353 related articles for article (PubMed ID: 26920889)
21. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.
Altman JK; Foran JM; Pratz KW; Trone D; Cortes JE; Tallman MS
Am J Hematol; 2018 Feb; 93(2):213-221. PubMed ID: 29139135
[TBL] [Abstract][Full Text] [Related]
22. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Inaba H; Rubnitz JE; Coustan-Smith E; Li L; Furmanski BD; Mascara GP; Heym KM; Christensen R; Onciu M; Shurtleff SA; Pounds SB; Pui CH; Ribeiro RC; Campana D; Baker SD
J Clin Oncol; 2011 Aug; 29(24):3293-300. PubMed ID: 21768474
[TBL] [Abstract][Full Text] [Related]
23. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.
Ganguly S; Cortes JE; Krämer A; Levis MJ; Martinelli G; Perl AE; Russell NH; Arunachalam M; Santos CD; Gammon G; Lesegretain A; Mires DE; Pham H; Wang Y; Khaled SK
Transplant Cell Ther; 2021 Feb; 27(2):153-162. PubMed ID: 33017662
[TBL] [Abstract][Full Text] [Related]
24. Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant.
Sandmaier BM; Khaled S; Oran B; Gammon G; Trone D; Frankfurt O
Am J Hematol; 2018 Feb; 93(2):222-231. PubMed ID: 29090473
[TBL] [Abstract][Full Text] [Related]
25. A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.
Hou P; Wu C; Wang Y; Qi R; Bhavanasi D; Zuo Z; Dos Santos C; Chen S; Chen Y; Zheng H; Wang H; Perl A; Guo D; Huang J
Cancer Res; 2017 Aug; 77(16):4402-4413. PubMed ID: 28625976
[TBL] [Abstract][Full Text] [Related]
26.
Naqvi K; Ravandi F
Leuk Lymphoma; 2019 Aug; 60(8):1866-1876. PubMed ID: 30997851
[TBL] [Abstract][Full Text] [Related]
27. Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia.
Paul S; DiPippo AJ; Ravandi F; Kadia TM
Future Oncol; 2019 Dec; 15(34):3885-3894. PubMed ID: 31559849
[TBL] [Abstract][Full Text] [Related]
28. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
[TBL] [Abstract][Full Text] [Related]
29. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
Ravandi F; Cortes JE; Jones D; Faderl S; Garcia-Manero G; Konopleva MY; O'Brien S; Estrov Z; Borthakur G; Thomas D; Pierce SR; Brandt M; Byrd A; Bekele BN; Pratz K; Luthra R; Levis M; Andreeff M; Kantarjian HM
J Clin Oncol; 2010 Apr; 28(11):1856-62. PubMed ID: 20212254
[TBL] [Abstract][Full Text] [Related]
30. Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib
Dumas PY; Naudin C; Martin-Lannerée S; Izac B; Casetti L; Mansier O; Rousseau B; Artus A; Dufossée M; Giese A; Dubus P; Pigneux A; Praloran V; Bidet A; Villacreces A; Guitart A; Milpied N; Kosmider O; Vigon I; Desplat V; Dusanter-Fourt I; Pasquet JM
Haematologica; 2019 Oct; 104(10):2017-2027. PubMed ID: 30923103
[TBL] [Abstract][Full Text] [Related]
31. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
Fathi AT; Blonquist TM; Hernandez D; Amrein PC; Ballen KK; McMasters M; Avigan DE; Joyce R; Logan EK; Hobbs G; Brunner AM; Joseph C; Perry AM; Burke M; Behnan T; Foster J; Bergeron MK; Moran JA; Ramos AY; Som TT; Rae J; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Levis MJ
Cancer; 2018 Jan; 124(2):306-314. PubMed ID: 28960265
[TBL] [Abstract][Full Text] [Related]
32. Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients.
Borthakur G; Zeng Z; Cortes JE; Chen HC; Huang X; Konopleva M; Ravandi F; Kadia T; Patel KP; Daver N; Kelly MA; McQueen T; Wang RY; Kantarjian H; Andreeff M
Am J Hematol; 2020 Nov; 95(11):1296-1303. PubMed ID: 32697348
[TBL] [Abstract][Full Text] [Related]
33. Transient exposure to quizartinib mediates sustained inhibition of FLT3 signaling while specifically inducing apoptosis in FLT3-activated leukemia cells.
Gunawardane RN; Nepomuceno RR; Rooks AM; Hunt JP; Ricono JM; Belli B; Armstrong RC
Mol Cancer Ther; 2013 Apr; 12(4):438-47. PubMed ID: 23412931
[TBL] [Abstract][Full Text] [Related]
34. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
Ravandi F; Alattar ML; Grunwald MR; Rudek MA; Rajkhowa T; Richie MA; Pierce S; Daver N; Garcia-Manero G; Faderl S; Nazha A; Konopleva M; Borthakur G; Burger J; Kadia T; Dellasala S; Andreeff M; Cortes J; Kantarjian H; Levis M
Blood; 2013 Jun; 121(23):4655-62. PubMed ID: 23613521
[TBL] [Abstract][Full Text] [Related]
35. Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in
Dumas PY; Villacreces A; Guitart AV; El-Habhab A; Massara L; Mansier O; Bidet A; Martineau D; Fernandez S; Leguay T; Pigneux A; Vigon I; Pasquet JM; Desplat V
Clin Cancer Res; 2021 Nov; 27(21):6012-6025. PubMed ID: 34400415
[TBL] [Abstract][Full Text] [Related]
36. Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia.
Liu LL; Zhang DH; Mao X; Zhang XH; Zhang B
Biochem Biophys Res Commun; 2014 Mar; 446(1):280-5. PubMed ID: 24582753
[TBL] [Abstract][Full Text] [Related]
37. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
38. A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).
Cooper TM; Sison EAR; Baker SD; Li L; Ahmed A; Trippett T; Gore L; Macy ME; Narendran A; August K; Absalon MJ; Boklan J; Pollard J; Magoon D; Brown PA
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28409853
[TBL] [Abstract][Full Text] [Related]
39. Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms.
Patel AB; Pomicter AD; Yan D; Eiring AM; Antelope O; Schumacher JA; Kelley TW; Tantravahi SK; Kovacsovics TJ; Shami PJ; O'Hare T; Deininger MW
Leukemia; 2020 Nov; 34(11):2981-2991. PubMed ID: 32409689
[TBL] [Abstract][Full Text] [Related]
40. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
Li J; Kankam M; Trone D; Gammon G
Br J Clin Pharmacol; 2019 Sep; 85(9):2108-2117. PubMed ID: 31173645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
